生物类改善病情抗风湿药可预防AA淀粉样变性进展至终末期肾病
该单中心回顾性分析纳入83例肾AA淀粉样变性患者(慢性炎症病相关34例、自身炎症综合征相关24例、特发性25例),接受细胞因子抑制性bDMARDs治疗,平均观察4.82年。bDMARD治疗显著降低CRP、血清淀粉样蛋白A和蛋白尿;进展至ESRD的预防率分别为60%、88%和81%。托珠单抗在降低CRP、预防ESRD和死亡方面优于其他bDMARDs。
要点
- bDMARD治疗可显著降低肾AA淀粉样变性患者的CRP、血清淀粉样蛋白A和蛋白尿。
- bDMARD治疗使60%慢性炎症病相关、88%自身炎症综合征相关和81%特发性AA患者免于进展至ESRD。
- 托珠单抗在降低CRP、预防ESRD和死亡方面优于其他bDMARDs。
核心结论
- bDMARDs可减轻多种疾病中的全身炎症,从而减少蛋白尿并预防ESRD。
- 托珠单抗在控制慢性炎症病和特发性AA患者的全身炎症方面比其他bDMARDs更有效,带来更好的肾脏和总体生存。
研究设计与样本
- 单中心回顾性分析,评估接受细胞因子抑制性bDMARDs治疗的肾AA淀粉样变性患者的肾脏结局和生存。
- 纳入慢性炎症病相关AA(n=34)、自身炎症综合征相关AA(n=24)和特发性AA(n=25),共83例。
- 平均观察期为4.82年。
主要发现
- bDMARD治疗显著降低C反应蛋白、血清淀粉样蛋白A和蛋白尿。
- 进展至ESRD的预防率:慢性炎症病相关AA为60%,自身炎症综合征相关AA为88%,特发性AA为81%。
- 托珠单抗用于34例慢性炎症病相关和特发性AA患者,在降低CRP、预防ESRD和死亡方面优于其他bDMARDs。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: AA amyloidosis (AA) can be the consequence of any chronic inflammatory disease. AA is associated with chronic inflammatory diseases (cid+AA), autoinflammatory syndromes (auto+AA) or AA of unknown origin or idiopathic AA (idio+AA). The major organ manifestation is renal AA that can progress to end-stage renal disease (ESRD) and multiple organ failure. MATERIALS AND METHODS: This study is a monocentric retrospective analysis of the renal outcome and survival of patients with cid+AA (n=34), auto+AA (n=24) and idio+AA (n=25) who were treated with cytokine-inhibiting biological disease-modifying antirheumatic drugs (bDMARDs). RESULTS: 83 patients with renal AA were identified and followed for a mean observational period of 4.82 years. C reactive protein (CRP), serum amyloid alpha and proteinuria were significantly reduced with bDMARD therapy. Progression to ESRD was prevented in 60% (cid+AA), 88% (auto+AA) and 81% (idio+AA) of patients. Tocilizumab was given to 34 patients with cid+AA and idio+AA and was more effective in reducing CRP and progression to ESRD and death compared with other bDMARDs. CONCLUSIONS: bDMARDs reduce systemic inflammation in various diseases, leading to a reduction of proteinuria and prevention of ESRD. Importantly, tocilizumab was more effective than other bDMARDs in controlling systemic inflammation in patients with chronic inflammatory diseases and idiopathic AA, leading to better renal and overall survival.
引用
- Kvacskay P, Hegenbart U, Lorenz HM, et al. bDMARD can prevent the progression of AA amyloidosis to end-stage renal disease. Ann Rheum Dis. 2024. PMID: 38653531. doi:10.1136/ard-2023-225114
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。